MedPath

Leptin

Generic Name
Leptin
Brand Names
-
Drug Type
Small Molecule
Chemical Formula
-
CAS Number
169494-85-3
Unique Ingredient Identifier
Q09SXY6BFI
Background

Although leptin is a circulating signal that reduces appetite, in general, obese people have an unusually high circulating concentration of leptin. These people are said to be resistant to the effects of leptin, in much the same way that people with type 2 diabetes are resistant to the effects of insulin. Thus, obesity develops when people take in more energy than they use over a prolonged period of time, and this excess food intake is not driven by hunger signals, occurring in spite of the anti-appetite signals from circulating leptin. The high sustained concentrations of leptin from the enlarged fat stores result in the cells that respond to leptin becoming desensitized.

Indication

Investigated for use/treatment in lipodystrophy and obesity.

Associated Conditions
-
Associated Therapies
-

Possible strategies to cross the blood–brain barrier

Lipid-soluble, low molecular weight, positively charged molecules can cross the BBB; others require transport systems. Five mechanisms facilitate solute movement: passive diffusion, solute carriers, carrier-mediated efflux, receptor-mediated transcytosis, and leukocyte diapedesis. Over 90% of drugs can't cross the BBB, prompting research into invasive and non-invasive delivery strategies, including drug modification, transport system use, efflux transporter inhibition, Trojan horse approach, chimeric peptides, monoclonal antibody fusion proteins, pro-drug bioconversion, nanoparticle technologies, gene therapy, intracerebral gene therapy, and intranasal drug delivery.
pmc.ncbi.nlm.nih.gov
·

The importance of gene–environment interactions in human obesity

The article reviews the role of gene-environment interactions (GEI) in obesity, highlighting how genetic predispositions interact with environmental factors to influence obesity risk. It discusses evidence from heritability, monogenic, and polygenic studies, emphasizing the complexity of these interactions and the challenges in studying them, including statistical modeling and replication issues. The review also explores potential biological mechanisms behind GEI and suggests future directions for research, including the application of findings in personalized medicine and lifestyle recommendations.
pmc.ncbi.nlm.nih.gov
·

Sugar-sweetened and diet beverage consumption is linked to increased CVD risk in youth with type 1 diabetes

High intake of sugar-sweetened beverages in youth with type 1 diabetes is linked to increased total cholesterol, LDL cholesterol, and triglycerides, indicating higher CVD risk. Diet beverage intake is associated with worse metabolic control and higher CVD risk factors, suggesting it may mark an unhealthy lifestyle. Reducing sugar-sweetened beverage intake is advised for youth with diabetes.
© Copyright 2025. All Rights Reserved by MedPath